Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates (“TA”), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites (“the Company”), […]
It’s been a busy week for Optimum, with some amazing original content from our clients, with this week’s podcast highlighting their expertise in cutting-edge lung cancer research. In our weekly hot topic article, they give predictions for the 2025 outlook following November’s London Life Sciences Week. We also have five clients nominated for the prestigious […]
During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm. Novo […]
Funding to support development of first-in-class CLDN1 targeted medicines Strong syndicate of international life science investors One of the largest ADC-focused private fundraisings globally in 2024 Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). […]
Novo Holdings today announced that it has agreed to acquire a majority stake in Stingray Marine Solutions, a market-leading aquaculture technology company that provides advanced solutions for a more sustainable fish farming industry. Stingray Marine Solutions (“Stingray”), founded in 2012 and headquartered in Oslo, Norway, specialises in intelligent aquaculture technology aimed at increasing sustainable salmon […]
